All Oncology News

Ten cancer programs that have developed pioneering solutions to address the challenges of treating cancer patients have received the Association of Community Cancer Centers' 2013 Innovator Awards.

The National Cancer Institute, part of the National Institutes of Health, has awarded two major grants totaling $26 million to leukemia researchers and physicians at the Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis.

The American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP) have released updated recommendations for HER2 testing in breast cancer.

Underlying mechanism for increased risk now defined.

Offering free head and neck cancer screenings annually to the community not only has the possibility of early detection, but also the opportunity – particularly in an urban city – to increase a person's understanding of risk factors that cause cancer, according to a new study from Henry Ford Hospital in Detroit.

In response to the growing trend of hospital consolidation, including questions about cancer care decision-making, cost impacts, and delivery of care, the ACCC Institute for the Future of Oncology has released a new white paper that provides perspectives on how these alignments are affecting cancer care providers, cancer programs, and the patients they serve.

Merrimack Pharmaceuticals, Inc. announced today that the last patient has been enrolled in the second cohort of a two-cohort randomized Phase 2 clinical trial of MM-121 in combination with paclitaxel in the neoadjuvant setting of HER2-negative breast cancer.

The investigational immunotherapy MK-3475 has demonstrated an objective response rate of up to 24% in patients with previously treated non-small cell lung cancer

A study of three diverse primary care practices tests the effectiveness of having doctors recommend counseling for colorectal cancer screening. Results found many patients do not follow through with the referral, but for those that do, some change their mind and have a test they might have avoided.

Initiative targets net reduction in annual operating expenses of approximately $2.5 billion by the end of 2015, this includes a plan for new workforce reductions of approximately 8,500 positions, in addition to pending, previously announced reductions.

Two question survey works as well as longer surveys.

Pertuzumab in combination with trastuzumab and chemotherapy has become the first FDA-approved neoadjuvant treatment for patients with breast cancer

World-class cancer research and treatment center is the latest to partner with OncLive to promote its research, events, and initiatives

Researchers find that patients are not referred for supportive care services.

Several recently published papers have introduced contradicting findings on the usefulness of BRAF status for predicting the presence of aggressive papillary thyroid cancer.

The IOM makes 10 recommendations for improving care.

The section of General Thoracic Surgery at UC Davis is offering Robotic Thoracic Surgery to further enhance our top regional minimally invasive thoracic surgery program.

The novel PLK1 inhibitor volasertib in combination with low-dose cytarabine has received a Breakthrough Therapy designation from the FDA for its potential as a treatment for patients with untreated AML.

The FDA has approved the first generic formulation of capecitabine, an oral chemotherapeutic that is currently approved to treat patients with metastatic colorectal cancer and metastatic breast cancer.

The FDA has granted Priority Review designation to dabrafenib (Tafinlar) and trametinib (Mekinist) as a combination treatment for patients with unresectable or metastatic melanoma with a BRAFV600E/K mutation.

The monoclonal antibody ofatumumab has received Breakthrough Therapy designation from the FDA that could allow for earlier use in patients with chronic lymphocytic leukemia.

The FDA's Oncologic Drugs Advisory Committee voted 13-0 with one abstention in support of pertuzumab in combination with trastuzumab and docetaxel for patients with HER2-positive breast cancer in the neoadjuvant setting.

Found to be helpful for patients with head and neck cancer.

A phase III trial examining the anti-CTLA-4 immune checkpoint inhibitor ipilimumab in men with metastatic castration-resistant prostate cancer failed to meet its primary endpoint of prolongation in overall survival.

The novel HDAC inhibitor entinostat in combination with exemestane has received a Breakthrough Therapy designation from the FDA for its potential to reverse resistance to hormonal therapies used to treat patients with advanced ER-positive breast cancer.

The hope for many targeted therapies is that they will eventually be used in patients with earlier stage disease; for the breast cancer drug pertuzumab (Perjeta), that hope is being put to the test.

The FDA has approved nab-paclitaxel plus gemcitabine as a first-line treatment for patients with metastatic adenocarcinoma of the pancreas, an area of high unmet need with few effective treatments.

The investigational MAGE-A3 immunotherapeutic did not significantly extend disease-free survival (DFS) in certain patients with postsurgical melanoma when compared with a placebo in a phase III study.

The first patient has been enrolled in a phase III clinical program investigating treatment with olaparib for patients with BRCA-mutated ovarian cancer, marking another step in the revived development of an agent once relegated to the sidelines.

UC Davis CLSP is a multidisciplinary program for comprehensive lung cancer screening.